Cutaneous lesions as presentation form of mantle cell lymphoma

Nayra Merino de Paz,1 Marina Rodríguez-Martín,1 Patricia Contreras Ferrer,1 Sonia García-Hernández,2 Nieves Hernández-León,2 Antonio Martín-Herrera,2 Antonio Noda-Cabrera1

1Dermatology and 2Pathology Department, Hospital Universitario de Canarias, University of La Laguna, La Laguna, Tenerife, Spain

Abstract

Mantle cell lymphoma is a type of non-Hodgkin lymphoma that affects extranodal areas, especially, bone narrow, digestive tract and Waldeyer ring. Other non-Hodgkin lymphomas that frequently involvem ent is very rare.1,2 MCL is characterized by specific morphologic, immunophenotypic and cytogenetic features [t(11;14)(q13;q32)] and cyclin D1 overexpression.3

Introduction

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma that frequently affects extranodal areas, especially, bone narrow, digestive tract and Waldeyer ring. Other areas can also be affected too, however skin involvement is very rare.1,2 MCL is characterized by specific morphologic, immunophenotypic and cytogenetic features [t(11;14)(q13;q32)] and cyclin D1 overexpression.3

Case Report

We report a 73-years-old man with a personal history of bilateral cataracts, facial right paralysis, vertiginous syndrome treated with trimetazidin and teleangiectatic rosacea without treatment. He was referred to our Department from Otolaryngology (ORL) where he was assessed for presenting nasal obstruction three months ago. No fever, asthenia or anorexia were reported. Physical examination revealed: i) papular erythematous, infiltrated, 2.5 × 2 cm of diameter lesion on nasal dorsum; ii) exulcerative, exudative lesion with erythematous edge about 3 × 4 cm of diameter in glans penis were observed (Figure 1). Blood test and cutaneous biopsies were performed.

Histological examination of cutaneous lesions on face and penis showed diffuse lymphocytic proliferation with middle size cells with irregular and clefted nucleous (Figure 2). Moderate mitotic activity was observed. Immunohistochemistry was positive for CD-20 and D1-Cyclin and negative for CD3 and CD10. Ki-67 showed a high proliferation rate (Figure 3). These results were consistent with mantle cell lymphoma (MCL). Blood tests, including hemogram, biochemistry and hepatic profile were in normal ranges. ORL study included a turbinate biopsy. Diffuse lymphocytic tumor proliferation infiltrates with middle size tumoral cells were observed. Tumoral cells showed clefted and irregular nucleous with granular chromat, moderate mitotic rate and apototic bodies. Bone narrow biopsy, thorax Rx, CT scan, MRI, PET and cytogenetic study were performed. Lymphocytic infiltrates showing features of MCL were observed in bone narrow. Multiple adenopathies and heterogeneous high intensity sings in both lungs were observed in PET studies (Figure 4). Cytogenetic studies were performed and t(11;14) was observed by FISH.

After hematologic and dermatologic assessment MCL IVA Ann Arbor stage and intermediate-high IPI diagnosis was established.

Four cycles of R-CHOP were administered every 21 days. A clear improvement after two cycles was observed (Figure 3). Two years later, the patient is still alive with Hematological, ORL and Dermatological periodical controls.

Discussion

The MCL represents around 10% of non-Hodgkin lymphomas (NHL). It usually affects medium or elder people. Skin involvement is rare, nevertheless, it can be the first manifestation of MCL. Only 19 cases of cutaneous MCL have been reported in the literature. It represents 2-6% of all NHL and the 17% are in stage IV. Men are more frequently affected than women (13:4) with a mean age of 63-years-old. Lesions usually appear in trunk, in contrast with our patient that presented the lesions first in face and genital area. A high variety in clinical appearance has been described. Nodular lesions are the most frequent clinical presentation, but macules, papules or plaques have been described too.

Our patient presented two different clinical forms; nasal dorsum with papular presentation and ulcerative clinical appearance in glans penis. Genital ulcerative form of cutaneous MCL is uncommon. Up to 82% of patients with skin lesions present coexisting extracutaneous involvem ent, so extension studies are necessary to find other affected organs including blood tests, Rx, CT scan, MRI and PET. MCL has a median survival of 3-5 years, with a better prognosis in patients with non-nodal disease. MCL is associated to a poor prognosis.4 The median survival time

Figure 1. Clinical appearance of cutaneous lesions on face and glans penis.
is approximately 3 years (range 2-5 years). The ten-year survival rate is only 5-10%. Younger age and limited diseases are favorable prognostic features. Survival behavior of patients with cutaneous involvement is shown in Table 1. The skin involvement is considerer as independent prognostic factor, but it is uncertain.3,4 Treatment is difficult. First-line treatments for solitary lesions include surgical excision, antibiotics, and radiotherapy. Systemic involvement needs an aggressive management. Only 30% of patients experienced a complete response. It is based in single alkylating agents, CVP (cyclophosphamide, vincristine and prednisone) and CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) regimens, Hyper-CVAD (hyperfractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone) with or without rituximab, R-CHOP (CHOP plus rituximab) or Hyper-CVAD with autologous stem cell transplantation. Our patient was treated with R-CHOP with a complete response. R-CHOP have showed a higher complete response rate than CHOP. Complications from chemotherapy may include infection, neutropenia, anemia, and thrombocytopenia, fatigue, neuropathy, dehydration after diarrhea or vomiting and cardiac toxicity from doxorubicin.5,6 Only ORL area involvement is also rare. So, our patient presented with a very unique clinical picture. In fact, sinonasal lymphomas are relatively uncommon and represent less than 1% of all head and neck malignancies. T/NK cell lymphoma is the most frequent in nasal cavity, however B-cell lymphoma is the main type in paranasal sinuses.5,6 So, here we present a rare case of MCL with cutaneous and nasal cavity lesions as presentation signs. The role of dermatologists is very important, in establishing an early diagnosis. We have to consid er this entity in the dermatologic differential diagnosis of tumours and we have to be aware about the importance of multidisciplinary approach.

Table 1. Skin manifestation of mantle cell lymphoma.

| N  | Author    | Age/Gender | Extracutaneous involvement | Stage     | Prognosis           |
|----|-----------|------------|-----------------------------|-----------|---------------------|
| 1  | Ellison   | 66M        | Yes                         | IV        | D (55 days after hospitalization) |
| 2  | Geerts    | 65F        | Yes                         | IVA       | D (1.5 years after diagnosis)   |
| 3  | Geerts    | 77F        | Yes                         | IVA       |                     |
| 4  | Bertero   | 51M        | Yes                         | IVA       | A (17 years after diagnosis)   |
| 5  | Bertero   | 78F        | No                          | IE        | D (3 years after diagnosis)    |
| 6  | Bertero   | 43M        | Yes                         | IVA       | A                   |
| 7  | Bertero   | 22M        | No                          | IE        | A                   |
| 8  | Marti     | 61F        | Yes                         | IVA       | D (15 months after diagnosis)  |
| 9  | Moody     | 47M        | Yes                         | IVA       | A (3 years after onset)        |
| 10 | Dubus     | 56M        | Yes                         | IVA       | D (1 year after treatment)     |
| 11 | Dubus     | 89M        | Yes                         | IVA       | D (5 days after diagnosis)     |
| 12 | Dubus     | 72M        | Yes                         | IVA       | A (1 year after treatment)     |
| 13 | Sen       | 85M        | Yes                         | IVB       | D (20 months after onset)      |
| 14 | Sen       | 76M        | No                          | IE        | A (30 months after onset)      |
| 15 | Sen       | 56M        | Yes                         | IVA       | A (21 months after onset)      |
| 16 | Sen       | 57M        | Yes                         | IVB       | D (19 months after onset)      |
| 17 | Sen       | 61M        | Yes                         | IVB       | D (17 months after diagnosis)  |
| 18 | Motegi    | 62M        | Yes                         | A         | (4 months after diagnosis)     |
| 19 | Estrozi   | 72M        | Yes                         | IVA       | A (6 months after diagnosis)   |
| 20 | Merino    | 73M        | Yes                         | IVA       | A (2 years after diagnosis)    |

Most of data adapted from Motegi S, Okada E, Naga Y, Tamura A, Ichikawa O. Skin manifestation of mantle cell lymphoma. Eur J Dermatol. 2004 Jul-Aug; 14(4):415-8. D, dead; A, alive.
References

1. Estrozi B, Sanches JA Jr, Varela PC, Bacchi CE. Primary cutaneous blastoid mantle cell lymphoma-case report. Am J Dermatopathol 2009;31:398-400.

2. Sen F, Medeiros LJ, Lu D, et al. Mantle cell lymphoma involving skin: cutaneous lesions may be the first manifestation of disease and tumors often have blastoid cytologic features. Am J Surg Pathol 2002 26:1312-8.

3. Motegi S, Okada E, Nagai Y, et al. Skin manifestation of mantle cell lymphoma. Eur J Dermatol 2006;16:435-8.

4. Lai R, Medeiros LJ. Pathologic diagnosis of mantle cell lymphoma. Clin Lymphoma 2000;1:197-208.

5. Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998;1:567-75.

6. Swerdlow SH, Kurzer M, Bernengo M, Buchner S. Cutaneous involvement in primary extracutaneous B-cell lymphoma. In: Weedon D, LeBoit P, Burg G, Sarasin A, eds. Pathology and Genetics of Tumors of the Skin: WHO Classification of Tumors. Lyon: IARC, 2005. pp 204-6.

7. Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk Lymphoma 2009;50:1937-50.

8. Van Prooyen Keyzer S, Eloy P, Delos M, et al. Sinonasal lymphomas. Case report. Acta Otorhinolaryngol Belg 2000;54:45-51.

9. Vidal RW, Devaney K, Ferlito A, et al. Sinonasal malignant lymphomas: a distinct clinicopathological category. Ann Otol Rhinol Laryngol 1999;108:411-9.

Figure 4. Upper side: Preauricular, retroauricular, occipital, submandibular, subcarinal, right hilum and groin lymphadenopathies, heterogeneous. Lower side: High intensity sings in both lungs were observed in PET studies.